Daniel Bos, MD, PhD; Marileen L. P. Portegies, MD; Aad van der Lugt, MD, PhD; et al.
free access
JAMA Neurol. 2014;71(4):405-411. doi:10.1001/jamaneurol.2013.6223
Bos et al investigate the relationship between intracranial carotid artery calcification as a marker of intracranial atherosclerosis and the risk of stroke in a white population. See also the Editorial by Chimowitz and Caplan.
-
Editorial
Is Calcification of Intracranial Arteries Important and How?
Marc I. Chimowitz, MBChB; Louis R. Caplan, MD
JAMA Neurol
Michael E. Hughes, PhD; John Peeler, BA; John B. Hogenesch, PhD; et al.
free access
JAMA Neurol. 2014;71(4):412-420. doi:10.1001/jamaneurol.2013.6225
Hughes et al quantitatively evaluate the performance of Alzheimer disease centers by analyzing copublication networks among the centers.
Graham S. Jackson, PhD; Jesse Burk-Rafel, MSc; Julie Ann Edgeworth, PhD; et al.
free access
JAMA Neurol. 2014;71(4):421-428. doi:10.1001/jamaneurol.2013.6001
Jackson et al determine the diagnostic accuracy of a prototype blood test for variant Creutzfeldt-Jakob disease and its suitability for clinical use and screening prion-exposed populations.
Joshua M. Shulman, MD, PhD; Lei Yu, PhD; Aron S. Buchman, MD; et al.
free access
JAMA Neurol. 2014;71(4):429-435. doi:10.1001/jamaneurol.2013.6222
Shulman et al evaluated 18 candidate single-nucleotide polymorphisms to determine whether Parkinson disease susceptibility loci are associated with parkinsonism or substantia nigra pathology.
Mikael Cohen, MD; Elisabeth Maillart, MD; Ayman Tourbah, MD, PhD; et al.
free access
JAMA Neurol. 2014;71(4):436-441. doi:10.1001/jamaneurol.2013.6240
Cohen et al collected data from patients with MS switching from natalizumab to fingolimod. They performed a survey-based, observational multicenter cohort study among MS tertiary referral centers. Main outcomes and measures were the occurrence of MS relapse during the washout period or during a 6-month follow-up period after the initiation of fingolimod.
Murray Grossman, MD, EdD; Lauren Elman, MD; Leo McCluskey, MD, MSc; et al.
free access
JAMA Neurol. 2014;71(4):442-448. doi:10.1001/jamaneurol.2013.6064
Grossman et al conduct a case-control study using phosphorylated tau to identify a biomarker for amyotrophic lateral sclerosis (ALS).
Janet Cady, BS; Erica D. Koval, BA; Bruno A. Benitez, MD; et al.
free access
JAMA Neurol. 2014;71(4):449-453. doi:10.1001/jamaneurol.2013.6237
Cady et al investigate whether p.R47H (rs75932628) in TREM2 is a risk factor for amyotrophic lateral sclerosis and assess whether TREM2 expression is dysregulated in disease.
Ji Yeoun Yoo, MD; Nishi Rampal, MD; Ognen A. Petroff, MD; et al.
free access
JAMA Neurol. 2014;71(4):454-462. doi:10.1001/jamaneurol.2013.6238
Yoo et al evaluate the incidence of brief ictal rhythmic discharges in critically ill patients and investigate their association with seizures and outcomes.
Aleksandar Videnovic, MD, MSc; Charleston Noble, BA; Kathryn J. Reid, PhD; et al.
free access
JAMA Neurol. 2014;71(4):463-469. doi:10.1001/jamaneurol.2013.6239
Videnovic et al examine the endogenous circadian rhythm of melatonin secretion in patients with Parkinson disease and healthy control individuals using a modified constant routine protocol to assess human endogenous rhythmicity.
Maxime Cadieux-Dion, BSc; Maude Turcotte-Gauthier, MSc; Anne Noreau, MSc; et al.
free access
JAMA Neurol. 2014;71(4):470-475. doi:10.1001/jamaneurol.2013.6337
Cadieux-Dion map and identify the causative gene in a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia variabilis.
Tobias Skillbäck, MD; Christoffer Rosén, MD; Fredrik Asztely, MD, PhD; et al.
free access
JAMA Neurol. 2014;71(4):476-483. doi:10.1001/jamaneurol.2013.6455
Skillb盲ck et al test the diagnostic performance of dementia cerebrospinal fluid biomarkers total tau (T-tau), phosphorylated tau (P-tau), and the T-tau to P-tau ratio for Creutzfeldt-Jakob disease.